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Background: To investigate the role of radiotherapy (RT) in and to suggest radiotherapeutic strategies for patients
presenting with disseminated cervical cancer.
Methods: We retrospectively analyzed 50 patients diagnosed as the disseminated cervical cancer with distant
lymph nodal or visceral organ metastasis between September 1980 and August 2012. Patients were divided into
two subgroups according to visceral organ metastasis: 35 patients diagnosed with distant lymph node metastasis
only (group A) and 15 patients with visceral organ metastasis (group B). All patients received external beam RT to
the pelvis (median dose 45 Gy) and high-dose rate intracavitary RT (median dose 30 Gy). Thirty-nine patients (78%)
received chemotherapy.
Results: Median follow-up time was 74 months. The 5-year pelvic control rate (PCR) was 85.8%, and the progression-free
survival (PFS), and overall survival (OS) rates were 28.7%, and 36.2%, respectively. The major treatment failure was
systemic progression (32 patients, 64%). The 5-year PCRs in groups A and B were 87.4% and 74.7%, respectively
(p > 0.05). Meanwhile, PFS and OS rates for group A were significantly better than those for group B (35.3% vs. 13.3%,
p = 0.010; and 46.3% vs. 13.3%, p = 0.009, respectively).
Conclusion: Our data revealed considerable prognostic heterogeneity in disseminated cervical cancer. Even though a
high PCR was achieved in patients treated with definitive RT, survival outcomes were dependent on progression of
visceral organ metastasis. Therefore, personalized RT and chemotherapy treatment strategies according to the presence
of visceral organ metastasis in disseminated cervical cancer patients may help improve clinical outcomes.
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Stage IVB cervical cancer is defined by the International
Federation of Gynecology and Obstetrics (FIGO) as: a
carcinoma that has extended beyond the true pelvis and
has spread to distant organs. As the FIGO staging
system does not differentiate between locations of lymph
node (LN) metastasis in stage IVB cancer, clinicians
often face diagnostic difficulties, particularly with metas-
tases to the mediastinal, axillary, or supraclavicular LNs.* Correspondence: ybkim3@yuhs.ac
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unless otherwise stated.Thus, many clinicians have regarded LN metastasis
beyond the extended field (EF) as stage IVB cancer, even
in the absence of visceral organ metastasis.
Patients with disseminated cervical cancer tend to
have very poor prognosis [1], and the treatment of pa-
tients with disseminated cervical cancer tends to vary ac-
cording to disease characteristics, patient symptoms, and
physician preference. However, no consensus has been
reached regarding the management of disseminated cer-
vical cancer due to its rarity, and there is a huge hetero-
geneity in the treatment of disseminated cervical cancer.
Nevertheless, while systemic or palliative radiotherapy
(RT) for pain, bleeding, or discomfort, is usually recom-
mended [2-6], little is known about the most effectiveis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ing disseminated cervical cancer patients.
Recently, a few reports have suggested that concurrent
chemoradiotherapy (CCRT) could increase survival in
cervical cancer patients with supraclavicular lymph node
(SCLN) involvement [7-9]. Other studies have found
that the combined use of RT and CTx with a curative
aim, for stage IVB cervical carcinoma, may increase sur-
vival [10-12]. Meanwhile, metastasis type has also been
reported to be associated with prolonged survival in
patients with disseminated cervical cancer [13]. Patients
with only lymphatic metastasis had a long-term survival,
but patients with hematogenous metastasis showed ex-
tremely poor prognosis. Thus, the purpose of this study
was to investigate the role of RT in and to suggest radio-
therapeutic strategies for treating disseminated cervical
cancer patients.
Methods
Eligibility
This retrospective study received approval from the
institutional review boards (No. 4-2015-0068). We retro-
spectively reviewed the medical records of patients initially
diagnosed with disseminated cervical cancer between
September 1980 and August 2012 at Yonsei Cancer Center,
Yonsei University College of Medicine, in Seoul, South
Korea. The present study included 50 cases of pathologic-
ally proven uterine cervical cancer treated with external
beam radiation therapy (EBRT) and high-dose rate intra-
cavitary irradiation (ICR). We defined disseminated cer-
vical cancer as follows: evidence of distant LN metastasis
beyond the EF (e.g., supraclavicular, mediastinal, axillary,
inguinal LNs) or hematogenous metastases to visceral
organs. The patients with inguinal LN metastasis with low
vaginal involvement were excluded. The diagnosis of
disseminated cervical cancer was based on physical exam-
ination, diagnostic imaging studies or pathologic findings
from biopsy. Patients who presented with LN metastases
within the EF or those with recurrent disease, were
excluded from the study.
The histological classification of uterine cervical can-
cer was based on the World Health Organization classi-
fication, and FIGO classification was used for clinical
staging. The routine procedure for staging included a
detailed history review, general physical examination (in-
cluding inguinal and supraclavicular nodal areas), pelvic
examination (including bimanual pelvic and rectal exami-
nations), laboratory tests (complete blood-cell count, serum
chemistries, urinalysis), colposcopy, standard chest radio-
graphs, intravenous pyelography, cystoscopy, and sigmoid-
oscopy. Optional studies (computed tomography (CT),
magnetic resonance imaging (MRI), positron emission
tomography-computed tomography (PET-CT), or bone
scan) were performed to evaluate the extent of disease.The distant spread of tumor was confirmed by imaging
studies and/or fine needle aspiration biopsy. In the image
interpretation of CT or MRI, the principal criterion for
positive node involvement was based on the axial diam-
eter of the LN. LNs larger than 1 cm in the short-axis
dimension were considered metastatic node involvement.
We also regarded central necrosis as a significant criterion
for metastatic disease within the LN [14,15]. In the image
interpretation of PET-CT, metastatic LN was defined as
follows: (1) the accumulated amount of fluorodeoxyglu-
cose greater than that in the liver or similar to that in the
brain cortex, or (2) the standardized uptake value of a
lesion that corresponded to the CT and that did not de-
crease in the delayed PET image compared with the initial
value [16]. In principle, it is essential to obtain tissue and
pathologically confirm for metastatic lesions. Because we
didn’t want to delay definitive treatment due to biopsy or
surgical procedures, all the visceral organ and paraaortic
lymph nodes metastases were confirmed by only imaging.
For patients with palpable neck, axilla, or the inguinal
LNs, percutaneous fine needle aspiration biopsy was per-
formed for twenty-one patients at the discretion of the
treating physician.
Treatment protocol
All the patients underwent the RT with definitive aims.
EBRT followed by high-dose rate ICR was delivered in
all patients. Parametrial, pelvic side wall, or node boost
wad performed after EBRT. EBRT was delivered to the
whole pelvis or EF through antero-posterior/postero-an-
terior portals or a four-field box technique, using mega-
voltage photon beams of 60Co or linear accelerators. The
superior borders of the whole pelvis and EF, usually L4-L5
and T11-T12 interfaces, respectively, were administered
EBRT. The daily fraction of EBRT was 1.8 or 2.0 Gy, ad-
ministered once daily for 5 days each week. During RT,
patients were assessed weekly for cervical tumor response.
High-dose rate ICR was delivered via a remote-controlled
after loading system. From 1979 to 1989, patients were
treated with a 60Co source, three times per week at 3 Gy
per fraction. After 1989, ICR with 192Ir was administered
at 5 Gy per fraction, up to a total dose of 30 Gy. Appli-
cator insertion was carried out on an outpatient basis
without anesthesia, and each treatment required approxi-
mately 10 to 15 minutes. Parametrial, or pelvic side wall
boost with central shielding, was administered to patients
with persistent parametrial disease, following planned
pelvic RT or between brachytherapy sessions. After the
patients underwent EBRT with the 45–50.4 Gy dose,
response of LNs was evaluated on CT images. If the treat-
ment response of the LNs was not complete remission
(non-CR), a node boost was delivered to the multiple
fields via the three-dimensional conformal technique. For
the para-aortic lymph nodes (PALN), the RT did not
Im et al. Radiation Oncology  (2015) 10:77 Page 3 of 8exceed 54 Gy, considering the toxicity of the small bowel.
In case of RT on the distant LNs or the metastatic bones,
EBRT to metastatic sites was administered concurrent
with pelvic RT. For the distant LNs, RT was administered
with the daily fraction of 1.8-2.0 Gy; and for the metastatic
bones, 3 Gy and total of 30–45 Gy. Korean national health
insurance does not cover expenses of modern radiation
techniques like IMRT or tomotherapy as an initial treat-
ment of cervical cancer which results in huge cost differ-
ence bigger than 5 times between 3DCRT and IMRT.
Therefore, physicians usually recommend 3D-CRT rather
than IMRT or tomotherapy in initially diagnosed cervical
cancer these days.
All the patients underwent platinum-based CTx except
for 11 patients who were treated only with RT. They were
composed of six who had been treated in the 1980s, two
elderlies, one with poor general condition, and two pa-
tients who refused to undergo CTx. The sequence of RT
and CTx was determined upon the physician’s discretion.
Platinum single-agent or platinum-based doublet regimens
were used. Twenty patients underwent platinum-based
single-agent regimens, and 19, platinum-based doublet
regimens. CCRT protocol was included two treatment
schemes. One scheme was composed of three CTx cycles
administered at the beginning of the first, fourth, and sev-
enth weeks of RT. The chemotherapeutic regimens con-
sisted of cisplatin 100 mg/m2 or carboplatin 400 mg/m2
followed by five consecutive daily infusions of 5-FU
1000 mg/m2. Since the publication of randomized trials,
weekly chemotherapeutic infusion has been performed
with cisplatin (40 mg/m2) or carboplatin (AUC, 2) during
radical RT [17]. For induction CTx, 100 mg/m2 of cisplatin
was infused, followed immediately by five consecutive daily
administrations of 1,000 mg/m2 of 5-fluorouracil, each as a
24-hour intravenous infusion. Other induction CTx regi-
men was paclitaxel 175 mg/m2 and carboplatin AUC 5.
Follow up and statistical analysis
Treatment responses were evaluated one month after
completion of RT via physical examination and imaging
studies. Complete remission was defined as the complete
disappearance of all measurable disease for at least one
month. Partial remission comprised a reduction in lesion
diameter of more than 50% with no demonstrable dis-
ease progression elsewhere. Stable disease consisted of a
decrease in lesion diameter of less than 50% or a 25% in-
crease in lesion diameter without appearance of any new
lesion. Progressive disease reflected an increase in lesion
diameter of more than 25% with or without appearance
of any new lesion. Patients who achieved CR for both
the primary cervical masses and metastatic LNs were
considered to have achieved overall CR.
Patients were followed-up every 3 months during the
second year after completion of therapy, and then every6 months thereafter. Recurrences in the cervix, vagina,
parametrium, or pelvic LNs were defined as pelvic fail-
ure. Systemic progression was defined as the appearance
of disease in visceral organs or distant LNs, distinct from
sites of the original disseminated disease. Overall survival
(OS) was calculated from the date of diagnosis to the date
of death, or date of last follow-up visit. Progression free
survival (PFS) was calculated as the time from the date of
diagnosis until the first reported occurrence of tumor pro-
gression, or death. The Kaplan-Meier method was used to
estimate pelvic control rate (PCR), PFS, and OS. Univari-
ate analysis of risk factors was performed by comparing
survival rates using the log-rank test. Multivariate analysis
was performed using a Cox proportional hazards model
and hazard ratios (HR) with a 95% confidence interval
(CI) to identify prognostic factors. A p-value of < 0.05 indi-
cated statistical significance.
Results
Patient characteristics and treatment profiles
Fifty patients were included in the present study. Patient
characteristics and treatment profiles are listed in Table 1.
The median age was 50 years (range, 22–77 years). Twelve
patients had severe vaginal bleeding which required vaginal
packing and blood transfusion. Squamous cell carcinoma
was the most common histologic subtype (42 patients,
84%). Sixteen patients (32%) had a hemoglobin level≤ 10 g/
dL before treatment and 36 patients (72%) had tumors meas-
uring > 4 cm in diameter. Thirty-nine patients (78%) received
CTx with RT. Patients had received CCRT in 28 (56%),
induction CTx in 11 (22%). EBRT was administered to the
whole pelvis in 15 (30%) patients, and EF in 35 (70%) patients.
The median dose of EBRT to the pelvis was 45 Gy (range,
43.2-54 Gy), and the median ICR dose was 30 Gy. The total
dose delivered to point A ranged from 64.5 to 94.25 Gy EQD2
(median, 75.5 Gy EQD2). Table 2 shows the sites of distant me-
tastases. SCLN was the most common distant metastatic site.
The patients were divided into two groups according
to the presence of visceral organ metastasis as follows:
Group A, patients with distant LN metastasis only (n = 35)
and Group B, patients with visceral organ metastasis (n = 15).
Group A included more cases of squamous cell carcinoma
than Group B (91.4% vs. 66.7%, p = 0.043). Patients in
Group A received more EF-RT to cover regional LN than
those in Group B (85.7% vs. 33.3%, p < 0.001). For Group
A patients, median doses of 45 Gy (range, 36–54 Gy) were
administered to the metastatic PALN, while a median dose
of 59.4 Gy (range, 44–60 Gy) was administered to distant
LNs. Other clinical characteristics and treatment profiles
between Groups A and B did not differ significantly.
Treatment response, patterns of failure and survival outcome
The median follow-up of surviving patients was 74 months
(range, 24–296 months). The results of treatment response
Table 1 Patient characteristics and treatment profile of whole patients and comparison of two subgroups
Characteristic Median (range)/no. of patients (%) p-
valueTotal Group A Group B
Age (year) NS
Median 50 49 51
Range 22-77 22-74 29-77
ECOG performance status NS
0-1 47 (94.0) 34 (97.1) 13 (86.7)
2-3 3 (6.0) 1 (2.9) 2 (13.3)
Histopathologic type 0.043
Squamous cell ca 42 (84.0) 32 (91.4) 10 (66.7)
Adenocarcinoma 5 (10.0) 3 (8.6) 2 (13.3)
Small cell ca 2 (4.0) 2 (13.3)
Adenosquamous cell ca 1 (2.0) 1 (6.7)
Pre-treatment Hb (g/dL) NS
≤ 10 16 (32.0) 10 (28.6) 6 (40.0)
>10 34 (68.0) 25 (71.4) 9 (60.0)
Tumor size (cm) NS
≤4 14 (28.0) 12 (34.3) 2 (13.3)
>4 36 (72.0) 23 (65.7) 13 (86.7)
Dissemination pattern
Group A 35 (70.0)
Group B 15 (30.0)
Treatment type NS
RT + CTx 39 (78.0) 25 (71.4) 14 (93.3)
RT alone 11 (22.0) 10 (28.6) 1 (6.7)
RT field <0.001
Whole pelvis 18 (36.0) 7 (20.0) 11 (73.3)
Extended 32 (64.0) 28 (80.0) 4 (26.7)
RT dose (Gy) NS
External dose 45.0 (43.2-54.0) 45.0(43.2-52.0) 45.0 (44.0-54.0)
ICR dose 30.0 (18.0-39.0) 30.0 (18.0-39.0) 30.0 (21.0-30.0)
Point A dose (EQD2) 75.5 (64.5-94.25) 72.9 (64.5-94.25) 75.5 (67.9-87.5)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; Ca, Carcinoma; Hb, hemoglobin; Group A, Distant lymph node metastasis only; Group B, Visceral organ
metastasis; RT, Radiotherapy; CTx, chemotherapy; ICR, intracavitary radiotherapy; Equivalent 2 Gy dose, EQD2.
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that 21 of the 35 patients achieved overall CR. There were
a total of 35 failures among 50 patients (70.0%), and sys-
temic progression was the dominant type of failure. Pelvic
failures were found in six patients (12%), and systemic
progression occurred in 32 patients (64%). Four patients
had both locoregional failure and systemic progression.
Eighteen of 50 patients (36%) survived until at least the
end of the follow-up period. The median PFS and OS
times were 9 and 23 months respectively. The 5-year PCR,
PFS, and OS were 85.8%, 28.7%, and 36.2%, respectively.
Univariate analysis was performed to identify significantprognostic factors affecting PCR, PFS, and OS. No signifi-
cant prognostic factors affecting PCR were detected. Uni-
variate analysis showed that tumor size > 4 cm and
dissemination pattern were independent prognostic fac-
tors for PFS and OS (p < 0.05) (Table 4). The 5-year PFS
and OS rates of Group A were significantly better than
those of Group B (35.3% vs. 13.3%, p = 0.01; 46.3% vs.
13.3%, p = 0.009); the two groups had similar 5-year PCR
(87.4% and 74.7%, respectively) (Figure 1). When patterns
of failure were analyzed in terms of the two significant fac-
tors, some differences were observed: Compare to patients
with small tumors, patients with large tumors were
Table 2 Distribution of disease characteristics
Metastatic sites Number of
patients
Distant LN metastasis
Supraclavicular LN 22
Inguinal LN 6
Mediastinal LN 3
Supraclavicular + mediastinal LN 1
Supraclavicular + axillary LN 1
Supraclavicular + axillary LN + inguinal LN 1
Supraclavicular + mediastinal + axillary + inguinal LN 1
Visceral organ metastasis only
Bone 6
Lung 2
Bone + lung 2
Bone + liver 1
Visceral organ + distant LN metastasis
Bone + inguinal LN 1
Bone + supraclavicular, inguinal LN 1
Lung + supraclavicular, inguinal LN 2
Abbreviations: LN lymph node.
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temic progression. Group B more frequently exhibited
systemic progression than Group A, despite a similar inci-
dence of pelvis recurrence (Table 5).
The results of multivariate analysis of PFS and OS and
are shown in Table 3. None of the prognostic factors
showed an association with PFS and OS on multivariate
analysis. However, patients with large tumors showed an
approximately two-fold increased risk of tumor progres-
sion compared to patients with small tumors. As well,
Group B patients exhibited an approximately two-fold
increased risk of progression and death compared to
those in Group A, with marginal significance (HR, 1.954
and 1.962, respectively). In Group A, we evaluated the
effect of CR on PFS and OS rates. (Figure 2); the 21
patients who achieved overall CR had significantly better
5-year PFS and OS rates than the 14 non-CR patients
(60.4% vs. 0%, p < 0.001; 73.3% vs. 7.1%, p < 0.001).Table 3 Response after treatment in Group A (n = 35)
CR (%) PR (%) SD (%) PD (%)
Primary cervical mass 29 (83) 5 (14) 1 (3) 0 (0)
Metastatic LNa) 22 (63) 12 (34) 0 (0) 1 (3)
Overallb) 21 (60) 12 (34) 1 (3) 1 (3)
Abbreviations: CR Complete remission, PR Partial remission, SD Stable disease,
PD Progressive disease, LN lymph node.
a)Metastatic LN: Pelvic, paraaortic, supraclavicular, mediastinal, or axillary LN.
b)Overall: Treatment response in all lesions (Primary cervical mass +Metastatic LN).Discussion
Owing to the recent advances in imaging technology,
disseminated disease is encountered more frequently dur-
ing the management of cervical cancer patients. However,
FIGO staging does not differentiate between different
types of metastatic spread, and no consensus has been
reached in terms of standardized treatment for dissemi-
nated disease. In fact, the National Comprehensive Cancer
Network Guidelines only offer treatment recommenda-
tions for distant metastasis [18]; two treatment plans have
been suggested according to whether the disease is amen-
able to local treatment. Nevertheless, criteria for amen-
ability to local treatment have also not been defined.
Therefore, determining which patients should receive
local treatment warrants investigation. As most dissemi-
nated cases present with locally advanced disease, the de-
cision to use RT rather than surgery would have a
significant influence on prognosis. In addition, as FIGO
classification does not provide nodal staging for cervical
cancer, no separate guidelines have been established to
treat nodal metastasis. Usually, radiation oncologists de-
sign radiation fields to cover regional nodal metastases for
the whole pelvis or EF. However, patients with LN metas-
tasis beyond the extended field, such as in the mediastinal,
axillary, or supraclavicular area, are considered to have
disseminated disease in accordance with stage IVB.
The prognoses of disseminated disease are heteroge-
neous, and dependent on the distribution of the dissem-
ination and tumor bulk [12,13]. Some recent studies
have shown that aggressive treatment using CCRT is
safe and effective for patients with limited LN metasta-
sis, such as SCLN metastasis [7-9,19,20]. Kim et al.
reported that the 3-year OS rate in patients with PALN
and SCLN metastases was 49%, when treated with cura-
tive CCRT [7]. They suggested that CCRT may be more
effective than systemic CTx for improving survival in
stage IVB cervical cancer patients with distant lymphatic
metastasis [9]. However, patients with visceral organ me-
tastasis were associated with a worse prognosis due to
systemic progression.
A personalized RT approach, based on the status of
visceral organ metastasis, may benefit patients with dis-
seminated cervical cancer. In patients with lymphatic
metastasis without visceral organ metastasis, definitive
RT with CTx might be recommended to achieve max-
imal local control and survival benefit. Several investiga-
tors reported that overall CR was achieved in 50 ~ 60%
patients treated with CCRT, including those with distant
lymphatic metastasis [7,9]. Our findings of overall CR in
60% of patients with distant LN were comparable to the
results of these two recent retrospective studies. Never-
theless, only systemic CTx was applied to patients with
distant lymphatic metastasis in one of these studies,
inducing CR in 0% of the patients [9]. In patients with
Table 4 Univariate and multivariate analysis of prognostic factors regarding progression free survival and overall
survival
Prognostic factor No. of
patients
Univariate analysis Multivariate analysis
5-y Survival rate (%) PFS OS
PFS p-value OS p-value HR (95% CI) p-value HR (95% CI) p-value
Age (y) NS NS — — — —
≤50 29 27.2 34.5
>50 21 30.6 35.9
Pathology NS NS — — — —
SCCa 42 27.5 33
non-SCCa 8 33.3 50
Pre-treatment Hb (g/dL) NS NS — — — —
≤10 16 18.8 18.8
>10 34 32.9 44.6
Tumor size (cm) 0.014 0.046 NS NS
≤4 14 40.5 53.8 1 1
>4 36 18.5 22.2 1.886 (0.777-4.577) 2.298 (0.839-6.292)
Treatment type NS NS — — — —
RT + CTx 39 27.2 37.4
RT alone 11 32.7 32.7
Dissemination pattern 0.010 0.009 0.075 0.076
Group A 35 35.3 46.3 1 1
Group B 15 13.3 13.3 1.954 (0.934-4.090) 1.962 (0.931-4.136)
Abbreviations: PFS progression free survival, OS overall survival, HR hazard ratio, NS not significant, SCCa squamous cell carcinoma, Hb hemoglobin, RT Radiotherapy,
CTx chemotherapy, LN lymph node, Group A Distant LN metastasis only, Group B Visceral organ metastasis.
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ment response was the only statistically independent
prognostic factors for OS [21]. The present study also
discerned that overall CR is an important prognostic
factor for 5-year OS rate. Therefore, implementing RT
concurrently with CTx, rather than systemic CTx alone,
may be beneficial to inducing overall CR. To achieve
maximum local control for these patients, EBRT onFigure 1 Progression free survival rate (a), and overall survival rate (b
Group B = Visceral organ metastasis).metastatic LNs in addition to pelvic RT with ICR might
be recommended.
Even though high pelvic controls rates were achieved
in patients with visceral organ metastasis treated with
definitive RT, the survival outcome was dependent on
progression of visceral organ metastasis. Therefore, the
importance of systemic CTx in delaying systemic pro-
gression should be emphasized. Recently, new cytotoxic) in group A and B (Group A = Distant LN metastasis only and
Table 5 The distribution of pattern of failures according
to tumor size and patient group
No. of
patients
Pelvic
recurrence
Systemic
progression
Tumor size (cm)
≤4 14 1 (7.1%) 6 (42.9%)
>4 36 5 (13.9%) 26 (72.2%)
Dissemination pattern
Group A 35 4 (11.4%) 20 (57.1%)
Group B 15 2 (13.3%) 12 (80.0%)
Abbreviations: LN lymph node, Group A Distant LN metastasis only, Group B
Visceral organ metastasis.
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gated for the treatment of recurrent or metastatic dis-
ease: Paclitaxel-based CTx has been shown to have a
radiosensitizing effect with objective response rates of
33–67.9% for carboplatin/paclitaxel studies and 29.1-
67% for cisplatin/paclitaxel studies [22]; Cisplatin/pacli-
taxel CTx was found to be the best combination for the
treatment of advanced or recurrent cervical cancer [3].
The overall response rate of combined docetaxel, carbo-
platin, and 5-fluorouracil in patients with metastatic cer-
vical carcinoma was 56% [23]. The response rate was 48%
among patients with recurrent, persistent, or metastatic
cervical cancer who received bevacizumab and cisplatin/
paclitaxel CTx [24]. CCRT and adjuvant gemcitabine/
cisplatin CTx in patients with stage IIB to IVA dis-
ease improved survival outcomes when compared with
CCRT [25]. CCRT followed by adjuvant gemcitabine/
cisplatin CTx may also benefit for disseminated uterine
cervical cancer patients. In clinical practice, we have
recently observed some patients with good responses after
upfront systemic CTx prior to RT, even though they are
not included in this analysis. Despite a lack of supporting
evidence, upfront systemic CTx might be a useful optionFigure 2 Comparison of survival curves according to treatment respo
Progression free survival rate, (b) overall survival rate.for patients with visceral metastasis. If the response after
chemotherapy is favorable, RT might be extended with
the consolidation aim of controlling residual disease
following CTx. Otherwise, the role of RT might be lim-
ited to palliative therapy to relieve vaginal bleeding and
pelvic pain, or to prevent vesicovaginal or rectovagi-
nal fistula caused by local progression. Palliative RT is
effective for providing relief from vaginal bleeding, pain,
and other symptoms [4,5,26]. The overall response rate
was more than 90% for vaginal bleeding control [5,26].
The present study also revealed that the 5-year PCR is
85.8%. Pelvic RT might be beneficial to palliate symp-
tom and delay pelvic progression in patients with visceral
organ metastasis.
The current study has several limitations. Since the
present study is a retrospective review covering a long
period, heterogeneity of patient characteristics might
have confused treatment, follow-up, and results. Hetero-
geneous treatments might be a confounding factor. Also,
unrecognized biases could not be considered in this
study. Because of the low incidence of this disease, a
small number of patients enrolled. Compared to the pre-
vious institutional studies, however, this study had the
greatest number of patients [11,12].
Conclusion
Notwithstanding the inherent drawbacks of a retrospect-
ive analysis, our data suggests the application of person-
alized radiotherapeutic strategies for patients presenting
with disseminated cervical cancer. Definitive RT, includ-
ing pelvis and affected distant nodal metastasis, may be
more beneficial to patients with disseminated cervical
cancer limited to distant LN metastasis only. Meanwhile,
in patients with visceral organ metastasis, systemic CTx
might be considered to delay systemic progression, while
administering RT to relieve local symptoms and to delay
pelvic progression.nse (complete remission (CR) vs. non-CR) in Group A. (a)
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